To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
What happens in the liver during cholestasis?
Imaging liver function
11-07-2012: Bile excretion is a major function of the liver to remove endogenous compounds such as bilirubin, and xenobiotics such as drugs from circulation. An impairment of the involved transport system results in an impairment of bile flow. This so called cholestasis is associated with an accumulation of potentially toxic substances in the liver and the systemic circulation.
Only few techniques for in vivo imaging of hepatobiliary excretory function have been reported so far. A team led by Michael Bauer from Jena University Hospital (Germany) now reports a new technique based on intravital microscopy, which has a great potential to differentiate between physiological and pathophysiological, i.e. cholestatic conditions.
The scientists first visualized hepatocellular transport by use of indocyanine green (ICG), an established dye with solely hepatobiliary excretion, which is applied in the clinical setting for assessment of excretory liver function. In order to optimize visualization and to expand the possibilities of analysis, the researchers tested an additional dye: DY635, a benzopyrylium based hemocyanine dye. This dye was chosen due to its binding capacity to plasma proteins and its relatively lipophilic character. In their study, Bauer and his team validated the dye for assessing hepatic excretory function. A primarily hepatic clearance of DY635 was confirmed by fluorophotometric determination of the dye in blood, bile and urine of rats.
For the study cholestasis was induced in rats by infection. The dyes were administered via the jugular vein catheter. Left liver lobes were examined by intravital microscopy using an inverted epifluorescence microscope. The researchers observed that ICG was delivered from the portal triad and distributed in sinusoids. While ICG was transported through the sinusoids towards the central vein, the dye was taken up by hepatocytes. Thereby, uptake exceeded excretion, resulting in a hepatocellular accumulation of ICG even in healthy animals. Under these conditions, the bile canaliculi could not be clearly visualized. In contrast to ICG, transcellular transport of DY635 was much faster, enabling a clear visualization of the bile canaliculi.
In cholestatic animals, hepatobiliary excretion of DY635 markedly differed from control animals. Intravital fluorescence microscopy of the liver revealed higher dye concentrations in the cholestatic liver. Thereby, DY635 could discriminate hepatic excretory dysfunction in cholestatic as opposed to control animals. Subsequent image analysis revealed that the dye accumulated within distinct regions, presumably single hepatocytes with an average size of 20–30 mm, predominantly around the central veins. These results are consistent with the fact that inflammation-induced down-regulation of canalicular transporters is most pronounced in pericentral hepatocytes.
DY635 even enabled an analysis at high resolution suggesting hepatocyte uncoupling as well as failure of primarily the canalicular pole, allowing in vivo insights into molecular mechanisms of this critical facet of hepatobiliary function.
The new approach may help to understand the effect of different forms of cholestasis. In addition, ICG and DY635 can be used as surrogates for various drugs enabling study of pharmocokinetics and tracking of xenobiotics.
P. Recknagel et al., J. Biophotonics 5(7), 571-581 (2012.
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Vivacta Initiates Development of Point of Care Test for Vitamin D
- 4Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 5A light switch inside the brain
- 6Researchers divide enzyme to conquer genetic puzzle
- 7New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 8Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 9Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 10Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- Going live – immune cell activation in multiple sclerosis
- DNA damage: The dark side of respiration
- EMBO announces new members for 2013
- Evotec and Harvard University to collaborate on development of new class of antibacterials
- Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013